Inovio Pharmaceuticals Inc. Stock Falls 12.2%, Underperforms Peers
Dow Jones2026/11/03 21:33This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Inovio Pharmaceuticals Inc. plunged 12.2% to $1.66 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 0.8% to 25,372.01 and the Dow Jones Industrial Average falling 0.4% to 51,786.72.
Inovio Pharmaceuticals Inc. closed 39.0% below its 52-week high of $2.72, which the company achieved on December 17th.
The stock underperformed when compared to some of its peers, as Johnson & Johnson fell 1.6% to $266.17, Statera Biopharma Inc. remained unchanged, and Pfizer Inc. fell 2.18% to $30.00.
Trading volume totaled 42.4 million, compared to the 50-day average of 9.5 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
November 03, 2026 16:33 ET (21:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
